Jeffrey William Henderson bought $350K of Becton, Dickinson and (BDX)
Executed Feb 10 2025, disclosed Feb 10 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Feb 10 2025), the stock returned -1.7% (delay-adjusted); from the execution session (Feb 10 2025), -1.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jeffrey William Henderson (Director) filed 5 Form 4 reports in the past 24 months (1 purchase, 4 sales), most often in Halozyme Therapeutics, Inc. (HALO). Across 1 priced purchase filing, the average 21-session return was -1.7% from execution and -1.7% from disclosure (delay-adjusted; derived). The largest single filing was $500K of HALO (10,000 sh × $50.01, as filed), executed Jan 6 2025.
Healthcare · Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products fo…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→